2024 · Xu — The Landscape of Smart Biomaterial-Based Hydrogen Therapy
Super-Abstract
This comprehensive review maps the rapidly evolving field of biomaterial-based H₂ delivery systems — engineered materials that can carry, target, and release molecular hydrogen precisely where disease processes occur. The authors explain how these ‚smart' biomaterials overcome the key limitation of conventional H₂ therapy (rapid dilution, no tissue targeting) by responding to disease-specific stimuli such as ROS, acidic pH, or near-infrared light. This is a literature review, not a new experimental study.
Commentary
One of the fundamental challenges with H₂ as a therapeutic is delivery: inhaled or dissolved H₂ distributes throughout the body and cannot accumulate at a lesion site in sufficient concentration. This review catalogues the growing toolkit of biomaterials designed to solve this problem — from nanoparticles and hydrogels to liposomes and metal-organic frameworks — each engineered to release H₂ in response to disease-specific microenvironmental triggers. The review also clarifies H₂'s mechanism: beyond direct ·OH and LPO scavenging, H₂ can suppress pro-inflammatory mediators (cytokines, ATP, HSP) and act as a signalling molecule activating cytoprotective pathways. The applications discussed span liver disease, metabolic syndrome, and immune modulation. Being a review, it does not offer new clinical efficacy data, but it provides a valuable map of where the engineering of H₂ delivery is heading.
Key quotes
- „the impact of H2 therapy is limited because hydrogen molecules predominantly depend on the systemic administration of H2 gas, which cannot accumulate at the lesion site with high concentration, thus leading to limited targeting and utilization.“ — the core delivery problem that biomaterial-based H₂ therapy aims to solve
- „the produced H2 from biomaterials not only can scavenge free radicals, such as reactive oxygen species (ROS) and lipid peroxidation (LPO), but also can inhibit the danger factors of initiating diseases, including pro-inflammatory cytokines, adenosine triphosphate (ATP), and heat shock protein (HSP).“ — H₂'s multifaceted mechanism beyond simple antioxidant action
- „the released H2 can further act as signal molecules to regulate key pathways for disease treatment.“ — H₂ as a signalling molecule — beyond radical scavenging
Our assessment
This is a comprehensive narrative review of an emerging bioengineering field. It does not generate new clinical evidence but is valuable for understanding where the frontiers of H₂ delivery technology are. The stimulus-responsive biomaterial approach addresses a genuine limitation of conventional H₂ therapy. However, nearly all described systems remain at the preclinical stage; clinical translation faces standard nanoparticle hurdles (toxicity, manufacturability, regulatory pathway). Readers should not interpret this review as evidence that biomaterial-based H₂ therapy is clinically proven.
Study design
- Type: narrative review of preclinical biomaterial engineering literature · n: n/a (literature synthesis) · H₂ delivery: multiple biomaterial platforms (nanoparticles, hydrogels, liposomes, MOFs) with stimulus-responsive release
- Result: no pooled effect sizes; identifies stimuli-responsive H₂ delivery as a strategy to overcome targeting limitations; highlights anti-ROS, anti-inflammatory, and signal-modulatory mechanisms
Abstract
Hydrogen (H2) therapy is an emerging, novel, and safe therapeutic modality that uses molecular hydrogen for effective treatment. However, the impact of H2 therapy is limited because hydrogen molecules predominantly depend on the systemic administration of H2 gas, which cannot accumulate at the lesion site with high concentration, thus leading to limited targeting and utilization. Biomaterials are developed to specifically deliver H2 and control its release. In this review, the development process, stimuli-responsive release strategies, and potential therapeutic mechanisms of biomaterial-based H2 therapy are summarized. H2 therapy. Specifically, the produced H2 from biomaterials not only can scavenge free radicals, such as reactive oxygen species (ROS) and lipid peroxidation (LPO), but also can inhibit the danger factors of initiating diseases, including pro-inflammatory cytokines, adenosine triphosphate (ATP), and heat shock protein (HSP). In addition, the released H2 can further act as signal molecules to regulate key pathways for disease treatment. The current opportunities and challenges of H2-based therapy are discussed, and the future research directions of biomaterial-based H2 therapy for clinical applications are emphasized.
Source & links
Screenshot of the PubMed page
This page mirrors the published abstract (© the authors / publisher) for reference and citation. The canonical source is the PubMed record linked above. This is not medical advice.